Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXALGO vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatments are inadequate
Mild to moderate pain,Fever
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Hepatic via CYP3A4 to hydromorphone and other inactive metabolites.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 20-30% bound to plasma proteins (primarily albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution (Vd): 90-120 L (approx. 1.3-1.7 L/kg), indicating extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Extended-release tablet: approximately 40% oral bioavailability due to first-pass metabolism. Bioavailability relative to immediate-release hydromorphone is comparable.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: start with 4 mg every 24 hours and titrate cautiously.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A or B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or use with extreme caution with 50% dose reduction.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for pediatric use; safety and efficacy not established.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at lowest dose (4 mg every 24 hours) and titrate slowly due to increased sensitivity and risk of respiratory depression.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Serious, life-threatening, or fatal respiratory depression; risk of opioid addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizure-prone patients; head injury; impaired renal or hepatic function.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydromorphone or any component of the product.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit and grapefruit juice as they may increase hydromorphone levels. Avoid alcohol and any food containing alcohol, as it can potentiate CNS depression. No other significant food interactions reported; however, a high-fat meal may delay absorption but does not affect overall exposure.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category C. First trimester: Limited data, but opioids cross placenta; risk of neural tube defects not established. Second/third trimester: Prolonged use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS). High doses near delivery may cause neonatal respiratory depression.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Hydromorphone is excreted in breast milk; M/P ratio approximately 2.6. Relative infant dose ~0.5-2% of maternal weight-adjusted dose. Use with caution; monitor infant for sedation, respiratory depression, and withdrawal. Consider risk of infant opioid exposure.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy may increase hydromorphone clearance due to increased renal blood flow and hepatic metabolism, potentially requiring higher or more frequent doses to maintain analgesia. However, no established guidelines; individualize dosing based on pain control and signs of respiratory depression. Avoid use during labor due to risk of neonatal respiratory depression.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
EXALGO (hydromorphone extended-release) is an opioid agonist indicated for pain severe enough to require daily, around-the-clock, long-term opioid treatment. Do not crush, chew, or dissolve tablets; this can cause rapid release and fatal overdose. Due to its high potency (5-7 times morphine), initiate cautiously in opioid-naïve patients. Use with naloxone available and educate on signs of respiratory depression. Avoid use in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected paralytic ileus. Monitor for opioid-induced constipation and consider bowel regimen. EXALGO's QD dosing is convenient but requires strict adherence to 24-hour interval.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take EXALGO exactly as prescribed; do not take more than prescribed or more often than every 24 hours.,Swallow tablets whole; do not crush, chew, or dissolve them as this can cause a fatal overdose.,Avoid alcohol and any other central nervous system depressants (e.g., benzodiazepines, other opioids) unless directed by your doctor, as they increase risk of severe sedation and respiratory depression.,Store in a safe place out of reach of children and others; dispose of unused tablets via a drug take-back program.,Do not stop taking EXALGO abruptly without consulting your doctor; withdrawal symptoms may occur.,Seek emergency help if you experience trouble breathing, extreme drowsiness, or fainting.,Do not drive or operate heavy machinery until you know how EXALGO affects you.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXALGO vs ACEPHEN, answered by our medical review team.
EXALGO is a Opioid Analgesic that works by Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXALGO and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXALGO is: Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXALGO and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXALGO is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data, but opioids cross placenta; risk of neural tube defects not established. Second/third trimester: Prolonged use may cause fe. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.